Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Lancet |
Vol/bind | 380 |
Udgave nummer | 9856 |
Sider (fra-til) | 1829-39 |
Antal sider | 11 |
ISSN | 0140-6736 |
DOI | |
Status | Udgivet - 2012 |
ID: 48584402